Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evaluation of Aducanumab for Alzheimer Disease

Evaluation of Aducanumab for Alzheimer Disease This Viewpoint details the development and regulatory path of aducanumab, a human IgG1 monoclonal antibody to treat Alzheimer disease, including termination of 2 clinical trials, identification of conflicting evidence of efficacy, and the FDA advisory committee vote against approval (final decision pending). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Evaluation of Aducanumab for Alzheimer Disease

JAMA , Volume 325 (17) – May 4, 2021

Loading next page...
 
/lp/american-medical-association/evaluation-of-aducanumab-for-alzheimer-disease-7cVM0ql6JV
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.3854
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint details the development and regulatory path of aducanumab, a human IgG1 monoclonal antibody to treat Alzheimer disease, including termination of 2 clinical trials, identification of conflicting evidence of efficacy, and the FDA advisory committee vote against approval (final decision pending).

Journal

JAMAAmerican Medical Association

Published: May 4, 2021

References